King of Prussia, Pennsylvania -- Personalized medicine technology company Genomind has garnered $3 million in new equity venture capital funding, according to an SEC regulatory filing.
Genomind is developing genetic testing technologies to bring personalized medicine to psychiatric care.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of six investors participated in the offering
Genomind is still seeking $5 million in additional financing, according to the filing.
Minimum investment size per investor was listed as $200,000.